Physician profile
Gregory J Dennis
NPI 1508976051
$3,917.51
in general payments reported to CMS, 2019-2025
28 companies · $23.19 in 2025
The $23.19 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,324 · 2020: $1,237 · 2021: $141 · 2022: $159 · 2023: $33.25 · 2025: $23.19.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $56.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $56.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $462.74 | 2019-2020 | |
| Lilly USA, LLC | $429.54 | 2019-2020 | |
| Pfizer INC. | $423.44 | 2019-2021 | |
| Amgen INC. | $414.80 | 2019-2021 | |
| Novo Nordisk INC | $408.03 | 2019-2020 | |
| Amarin Pharma, INC. | $241.74 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $240.64 | 2019-2020 | |
| Astellas Pharma US INC | $226.60 | 2019 | |
| Merck Sharp & Dohme LLC | $177.49 | 2019-2020 | |
| Si-Bone, INC. | $145.34 | 2022 | |
| Novartis Pharmaceuticals Corporation | $100.13 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $97.65 | 2019-2020 | |
| Eisai INC. | $94.83 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $78.19 | 2019-2020 | |
| Glaxosmithkline, LLC. | $68.63 | 2020-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $50.60 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $39.35 | 2019 | |
| Corcept Therapeutics | $33.25 | 2023 | Korlym |
| E.R. Squibb & Sons, L.L.C. | $27.24 | 2019 | |
| Antares Pharma, INC. | $26.29 | 2019 | |
| Genentech USA, INC. | $25.56 | 2019 | |
| Abbott Laboratories | $24.25 | 2021 | |
| Abbvie INC. | $17.41 | 2020 | |
| Ibsa Pharma INC. | $14.43 | 2020 | |
| Dexcom, INC. | $13.86 | 2022 | |
| Allergan, INC. | $12.35 | 2020 | |
| Horizon Therapeutics Plc | $11.89 | 2020 | |
| Nalpropion Pharmaceuticals LLC | $11.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Dennis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.